U.S. Colorectal Cancer Screening Market Poised to Grow at a Robust Pace Due to Increasing Colorectal Cancer Incidences

I am Ben Stiller. I hold full responsibility for this content, which includes text, images, links, and files. The website administrator and team cannot be held accountable for this content. If there is anything you need to discuss, you can reach out to me via benstiller704@gmail.com email.

Disclaimer: The domain owner, admin and website staff of Times Square Reporter, had no role in the preparation of this post. Times Square Reporter, does not accept liability for any loss or damages caused by the use of any links, images, texts, files, or products, nor do we endorse any content posted in this website.

U.S. Colorectal Cancer Screening Market Poised to Grow at a Robust Pace Due to Increasing Colorectal Cancer Incidences
The U.S. colorectal cancer screening market has gained significant prominence over the recent years owing to the increasing number of colorectal cancer cases in the country.

U.S. Colorectal Cancer Screening Market Poised to Grow at a Robust Pace Due to Increasing Colorectal Cancer Incidences

The U.S. colorectal cancer screening market has gained significant prominence over the recent years owing to the increasing number of colorectal cancer cases in the country. Screening tests help detect colorectal cancer at an early stage when the odds of successful treatment are higher. Some of the commonly used screening tests in the market are fecal occult blood tests, sigmoidoscopy, and colonoscopy. Colonoscopy allows doctors to examine the entire colon and detect polyps or cancers. The procedure is considered as the gold standard for colorectal cancer screening and is highly effective at detecting pre-cancerous polyps.

The Global Colorectal Cancer Screening Market Size is estimated to be valued at US$ 5,952.2 Mn in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the U.S. colorectal cancer screening market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Quidel Corporation, Novigenix SA and Among Others. Some of the leading players are focusing on ramping up production capacities and capabilities through strategic collaborations to meet the growing demand.

The market provides significant opportunities for players involved in developing advanced diagnostic methods, portable diagnostic devices, non-invasive screening tests. Moreover, growing awareness about early cancer detection and increasing emphasis on preventive healthcare is expected to boost market growth.

The major players are committed towards global expansion to expand their geographic footprint in high potential markets. For instance, Polymedco launched its product offerings in several European and Asian countries in last few years. Other players are also exploring opportunities in emerging markets through partnerships with regional diagnostic service providers.

Market Drivers:

Increasing colorectal cancer incidences: According to estimates, colorectal cancer incidences have increased considerably over the past few decades. It is one of the most commonly occurring cancers in the US. Rising disease prevalence is the key driver fostering the demand for effective screening tests.

Market Restraints: 

High Cost of Colorectal Cancer Screening: Regular screening tests can benefit in early cancer detection but come at a higher cost which may not be affordable for all. This remains a major barrier especially in developing regions hampering wider screening uptake.

Segment Analysis 

The U.S. colorectal cancer screening market is dominated by fecal occult blood test (FOBT) sub-segment due to its cost-effectiveness and non-invasive nature. It accounted for over 35% share of the overall market in 2024. FOBT screens for hidden blood in stool, which could be a sign of colorectal cancer or other conditions affecting the colon or rectum. The other major screening method is fecal immunochemical test (FIT) which detects human hemoglobin in stool samples and dominated 23% share owing to its higher sensitivity and specificity for detecting lower gastrointestinal bleeding compared to guaiac FOBT.

Global Analysis

The Western region led the U.S. colorectal cancer screening market with over 45% share in 2024 owing to supportive initiatives and frequent recommendation of screening by physicians. States like California, Texas and Florida accounted for the highest number of screenings performed annually. The Northeast region is anticipated to witness growth of 8% during the forecast period. Rising awareness programs and availability of affordable healthcare are supporting screening uptake. However, the Southern states exhibit lower screening rates currently due to lack of sufficient coverage and access barriers in rural areas. Concerted efforts by healthcare organizations and institutions can boost screening acceptance in these regions.

What Are The Key Data Covered In This U.S. Colorectal Cancer Screening Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the U.S. Colorectal Cancer Screening's growth between 2024 and 2031.

:- Accurate calculation of the size of the U.S. Colorectal Cancer Screening and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- U.S. Colorectal Cancer Screening Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of U.S. Colorectal Cancer Screening vendors

FAQ’s

Q.1 What are the main factors influencing the U.S. Colorectal Cancer Screening?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top U.S. Colorectal Cancer Screening companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the U.S. Colorectal Cancer Screening’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

 

Get more insights on this topic: https://www.marketwebjournal.com/colorectal-cancer-screening-market-in-u-s-is-driving-screening-adoption-by-rising-cancer-cases/

What's your reaction?

Comments

https://www.timessquarereporter.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!

Facebook Conversations